New Delhi, Apr 26 (PTI) Zydus Lifesciences on Saturday said the US health regulator has issued six observations after inspecting its Gujarat-based API manufacturing unit.
"We wish to inform that the US Food and Drug Administration (USFDA) conducted a surveillance inspection at the group's API (active pharmaceutical ingredient) unit located at Dabhasa in Gujarat," the drug firm said in a regulatory filing.
The inspection was conducted from April 21-25, 2025.
"The inspection concluded with 6 observations and none of them were related to data integrity," Zydus Lifesciences said.
The company is confident of addressing the observations expeditiously, it added. PTI MSS ANU ANU
/newsdrum-in/media/agency_attachments/2025/01/29/2025-01-29t072616888z-nd_logo_white-200-niraj-sharma.jpg)
Follow Us